PCSK9 and familial hypercholesterolemia: Nonetheless, the association of the C679X variant with low fasting glucose in young participants that have no risk factors for diabetes, suggests that the PCSK9 inhibitor drugs which mimic these variants might even confer protection against both diabetes and hypercholesterolemia.